RSS Feeds
Holding GUSTO Up to the Light
- Kerry L. Lee, PhD;
- Robert M. Califf, MD;
- John Simes, MD;
- Frans Van de Werf, MD;
- Eric J. Topol, MD; and
- for the GUSTO Investigators
- From Duke University Medical Center, Durham, North Carolina; the University of Sydney, Sydney, New South Wales, Australia; Universitaire Ziekenhuizen Leuven, Leuven, Belgium; the Cleveland Clinic Foundation, Cleveland, Ohio. For the GUSTO Investigators. Requests for Reprints: Kerry L. Lee, PhD, Clinical Trials Coordinating Center, Box 3363, Duke University Medical Center, Durham, NC 27710. Grant Support: By a combined grant from Bayer, CIBA-Corning, Genentech, ICI Pharmaceuticals, and Sanofi Pharmaceuticals.
Abstract
The Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) trial, a recent randomized “megatrial” of thrombolytic therapies in acute myocardial infarction, showed a statistically significant decrease of 30-day mortality in patients treated with accelerated-dose tissue plasminogen activator (tPA) compared with streptokinase. The therapeutic and cost implications of the results have been intensely scrutinized, and several commentaries have been written on the interpretation of the study. Questions have been raised about the treatment benefit in certain subgroups, the validity of the results because of the open-label design, the relevance of a 1% absolute benefit in mortality rates, the cost-effectiveness of the drug, and the generalizability of the results. These issues are all important considerations for translating the results of this study into clinical practice worldwide.
This article sheds additional light on the interpretation of GUSTO, clarifies misconceptions that may have clouded understanding of the trial results, and discusses the contributions of this trial in advancing our understanding of modern myocardial reperfusion therapy.
- Copyright ©2004 by the American College of Physicians
